Dolutegravir Appears Superior to Raltegravir Among HIV Salvage Patients Interim 24-week results from a Phase III study
comparing the investigatory dolutegravir to raltegravir among
HIV-positive individuals who have experienced treatment failure suggest
that dolutegravir is superior at suppressing virus.
Baby Born With HIV Is Functionally Cured After being treated with meds for 18 months right after being born with HIV, a now 2-year-old child seems to be functionally cured of the virus.